CD4 and non-small cell lung carcinoma: A meta-analysis has also shown that combining ginsenoside Rg3 with chemotherapy leads to increased peripheral blood T lymphocyte subsets, including CD3, CD4, CD8, and CD4/CD8, in non-small cell lung cancer (NSCLC) patients compared to chemotherapy alone, indicating improved immune system function in these patients (30).